{"title": "Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review", "author": "Lee; Jae Kyung; Shin; Ok Sarah", "url": "http://www.koreamed.org/SearchBasic.php?RID=2529266", "hostname": "koreamed.org", "description": "COVID-19; Pandemics; Platforms; Vaccines", "sitename": "KoreaMed", "date": "2022-04-29", "cleaned_text": "1. World Health Organization (WHO). WHO coronavirus (COVID-19) S, Abrignani S, Klenk HD, et al. SARS: beginning to understand a new virus. Nat Rev Microbiol. 2003; 1:209-18. 3. Janeway Jr CA, Travers P, MJ. The distribution and functions of immunoglobulin isotypes. In Janeway Jr CA, Travers P, Walport M, Shlomchik MJ, editors. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Science;2001. 7. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw immunogenicity, efficacy and effectiveness of inactivated influenza vaccines in healthy pregnant women and children under 5 years: an evidence-based clinical review. Front Immunol. 2021; 12:744774. 9. Pepin S, Dupuy M, Borja-Tabora CF, Montellano M, Bravo L, Santos J, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: a multi-season randomised placebo-controlled trial in the Northern and Southern hemispheres. Vaccine. 2019; 37:1876-84. 10. Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis. 2013; 17:e939-44. 12. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical Tanriover Azap A, Akhan S, al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398:213-22. 14. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020; 182:713-21. 15. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, phase 1/2 trial. Lancet Infect Dis. 2021; 21:39-51. 16. Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine. 2021; 17. XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: test-negative case-control real-world 18. Russell WC. Adenoviruses: update structure 1):1-20. Shahin M, Buekers T, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Ther. 2002; 9:553-66. 20. VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017; 13:613-20. 22. Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes S, al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396:467-78. 24. Voysey M, SA, Madhi LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled of four 2021; 397:881-91. 25. Sadoff J, Le Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021; 384:1824-35. 26. Bos R, Rutten der Lubbe MJ, Hardenberg G, Wegmann F, a prefusion-stabilized SARS-CoV-2 Spike immunogen humoral OV, AS, rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397:671-81. 28. Eichinger 2021; 385:e11. 29. Health Alert Network; Centers for Disease Control and Prevention (CDC). Emergency preparedness and response: cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383:2603-15. 31. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. structure of N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021; 385:1761-73. 33. al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021; 595:572-7. 34. Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron. Viruses. 2022; 14:79. 35. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021; 2:100355. 36. Stanojevic M, Geiger A, Ostermeier B, Sohai D, Lazarski C, Lang H, et al. Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. Cytotherapy. 2022; 24:10-5. 37. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021; 385:585-94. prime-boost elicits potent Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. 2021; 385:2421-30. 40. Perrie Y, Crofts F, Kastner E, Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020; 383:2427-38. 42. El Sahly HM, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021; 385:1774-85. 43. Self JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions: United Finocchiaro G, Claudia M, Gianatti A, Delialis D, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2022; 27:251-61. 45. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021; 385:1078-90. 46. Colella G, Orlandi M, COVID-19 J Neurol. 2021; 268:3589-91. 47. Repajic M, Lai XL, Xu P, Liu A. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. Brain Behav Immun Health. 2021; 13:100217. 48. Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021; 21:450-2. Teixeira al. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection BALB/c mice. Clin Vaccine Immunol. 2006; 13:930-5. 50. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine. 2000; 18:2592-9. 51. Rai N, Kaushik P, Rai A. Development of rabies DNA vaccine using a recombinant plasmid. Acta Virol. 2005; 49:207-10. 52. Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021; 31:100689. RN, Turner HL, et designed prefusion MERS-CoV spike Proc al. Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza A, Stertman L. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One. 2012; 7:e41451. 56. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021; 385:1172-83. 57. Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. Adjuvanting a subunit COVID-19 vaccine to induce "}